Navigation Links
Tengion Addresses Recent Trading Activity in its Common Stock
Date:2/16/2011

EAST NORRITON, Pa., Feb. 16, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that it has been engaged in negotiations with a publicly traded company relating to the acquisition of Tengion through a stock-for-stock merger.  As a result of the recent increases in the trading price and volume of Tengion's common stock, Tengion's potential acquirer has terminated merger negotiations.

As has previously been stated in the Company's filings with the Securities and Exchange Commission, Tengion believes it has sufficient cash to fund its operations into April 2011.  If Tengion cannot secure either a sale transaction or alternative financing through partnership or equity investment, Tengion may need to take steps to wind down its operations so as to preserve the value of its assets for the benefit of its creditors and stockholders.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
2. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
3. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
4. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
5. Tengion Appoints A. Brian Davis Chief Financial Officer
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
8. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
9. Tengion Announces Second Closing of Series C Financing
10. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
11. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... SAN DIEGO and PRINCETON, N.J. ... Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic ... conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), ... the 2014 Exosomes & SingleCell Analysis Summit. ... of Exosome Sciences will give a presentation entitled: "Exosomes: ...
(Date:9/17/2014)... JH Technologies announces the grand ... JH Technologies, a leader in sales and support ... expanded partnership with Leica Microsystems into the Southern California ... solutions will be featured at the grand opening slated ... facility is located within the JH Technologies office’s at ...
(Date:9/17/2014)... -- Intarcia Therapeutics, Inc. today announced the ... the cost and predictability of non-adherence in type 2 ... of the European Association for the Study of Diabetes ... , Ph.D., of Analysis Group, Inc. presented data from ... studies to characterize the prevalence of non-adherence and serial ...
(Date:9/17/2014)... SOUTH SAN FRANCISCO, Calif. , Sept. 17, 2014 ... VCYT ), a molecular diagnostics company pioneering the field ... M. Hall to chief operating officer. Mr. ... to spearhead the company,s commercial entry into endocrinology. Since ... service operations, as well as managed care and billing ...
Breaking Biology Technology:Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... uniform magnetic fields to drive iron-bearing nanoparticles to metal ... a drug payload that successfully prevents blockages in those ... better results at a lower dose than conventional non-magnetic ... the research is the latest in a series of ...
... ... creating an integration breakthrough with toxicology software and study-scaled capsule filling device. ... Greifensee, ... Data System (PDS) and METTLER TOLEDO (MT), global manufacturer of weighing technology, announce ...
... ... ... incredible chances to meet Taylor Swift . 100% of the proceeds will go towards the charity., ... 5/8 in Moline, IL 6/2 in Washington, D.C. This ...
Cached Biology Technology:Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 2Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 3Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 4Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies 2Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies 3Meet Taylor Swift! Concert Tickets with Meet and Greet Opportunities to Benefit City of Hope 2
(Date:9/17/2014)... great deal about complex social behavior by studying nonhuman ... teach too. , With their unusually large brains relative ... in a complex social environment---not merely in a large ... but in a dynamic setting of alliances and competitors. ... dolphins, whales, primates, and social carnivores, like hyenas and ...
(Date:9/16/2014)... Ohio (September 17, 2014)The North American Menopause Society ... the comprehensive care of midlife womenon everything from ... "The North American Menopause Society Recommendations for Clinical ... in the Society,s journal Menopause . This ... for the care of midlife women freely available ...
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... impact on the diversity of beneficial microbial fungi known ... and maintenance of healthy ecosystems, according to new research ... Environmental Microbiology . The conclusions could have important implications ... tackle food security issues. The study was led ...
... FL. -- The first genetic study to compare nuclear ... manatees confirmed their designation as separate subspecies. Belize,s manatees, ... raising questions about their long-term genetic viability. The ... breeding population of Antillean manatees and is touted by ...
... University,s expanding research, education and entrepreneurial endeavors in ... of the Center for Photonics Innovation. The ... the center, which will combine university research and ... and engineering, and bioengineering. The center,s research ...
Cached Biology News:Farm management choice can benefit fungi key to healthy ecosystems 2Manatee subspecies genetically confirmed, but diversity challenge looms 2Manatee subspecies genetically confirmed, but diversity challenge looms 3Focus on photonics 2
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
...
... HM-4000 Multidizer is designed with a ... orbital, rotating - all in one unit. ... Two independently operating compartments allow for hybridization ... or motion , The upper chamber ...
... sleek design loaded with class-leading features, the 1400 Series ... work is safe and consistent every time you use ... 1400 Series reduces power consumption by as much as ... over the life of the cabinet. Multiply this ...
Biology Products: